Gefitinib induction of in vivo detectable signals by Bcl-2/Bcl-xLmodulation of inositol trisphosphate receptor type 3

Clinical Cancer Research

Volumn 14, Issue 16, 2008, Pages 5209-5219

  Zannetti, Antonella ^a   Lommelli, Francesca ^a   Fonti, Rosa ^a   Papaccioli, Angela ^a   Sommella, Jvana ^a   Lettieri, Anna ^a   Pirozzi, Giuseppe ^b   Bianco, Roberto ^c   Tortora, Giampaolo ^c   Salvatore, Marco ^a,d   Del Vecchio, Silvana ^a,d  

^a CNR   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c Department of Endocrinology and Molecular and Clinical Oncology ^*  (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; INOSITOL TRISPHOSPHATE; INOSITOL TRISPHOSPHATE RECEPTOR TYPE 3; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PROTEIN BCL 2; PROTEIN BCL XL; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; INOSITOL 1,4,5 TRISPHOSPHATE RECEPTOR; PROTEIN BCL X; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CASE REPORT; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG CANCER; MALE; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANIMAL; APOPTOSIS; DRUG EFFECT; IMMUNOPRECIPITATION; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; MIDDLE AGED; MITOCHONDRIAL MEMBRANE POTENTIAL; NEOPLASM; NUDE MOUSE; PHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; WESTERN BLOTTING;

AGED; ANIMALS; APOPTOSIS; BCL-X PROTEIN; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOPRECIPITATION; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; LUNG NEOPLASMS; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, NUDE; MIDDLE AGED; MITOCHONDRIA; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; QUINAZOLINES; RADIOPHARMACEUTICALS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TECHNETIUM TC 99M SESTAMIBI;

EID: 52649118041     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0374     Document Type: Article

References (41)

1. Ono M, Kuwano M. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res 2006;12:7242-51.
2. Herbst RS, Fukuoka M, Baselga J. Gefitinib-novel targeted approach to treating cancer. Nat Rev Cancer 2004;4:956-65.
3. Brehmer D, Greff Z, Godl K, et al. Cellular targets of gefitinib. Cancer Res 2005;65:379-82.
4. Sun S, Schiller JH, Spinola M, Minna JD. New molec-ularly targeted therapies for lung cancer. J Clin Invest 2007;117:2740-50.
5. Johnson BE, Janne PA. Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Cancer Res 2005;65:7525-9.
6. Bianco R, Melisi D, Ciardiello F, Tortora G. Key cancer cell signal transduction pathways as therapeutic targets. Eur J Cancer 2006;42:290-4.
7. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
8. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
9. Engelman JA, Janne PA, Mermel C, et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefiti-nib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A 2005;102:3788-93.
10. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5900-9.
11. Sordella R, Bell DW, Haber DA, Settleman J. Gefiti-nib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004;305:1163-7.
12. Weinstein IB. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 2002;297:63-4.
13. Costa DB, Halmos B, Kumar A, et al. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med 2007;4:1669-79.
14. Kuroda J, Puthalakath H, Cragg MS, et al. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci USA 2006;103:14907-12.
15. PaoW, MillerVA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
16. Kwak EL, Sordella R, Bell DW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A 2005;102:7665-70.
17. Kobayashi S, BoggonTJ, DayaramT, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92.
18. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43.
19. Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007;104:20932-7.
20. Deng J, ShimamuraT, Perera S, et al. Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion. Cancer Res 2007;67:11867-75.
21. Reed JC. Proapoptotic multidomain Bcl-2/Bax- family proteins: mechanisms, physiological roles, and therapeutic opportunities. Cell Death Differ 2006;13:1378-86.
22. 2+homeostasis and apoptosis. EMBO J 2004;23:1207-16.
23. Oakes SA, Scorrano L, Opferman JT, et al. Proapoptotic BAX and BAK regulate the type 1 inositol trisphos-phate receptor and calcium leak from the endoplasmic reticulum. Proc Natl Acad Sci USA2005;102:105-10.
24. Chen R, Valencia I, Zhong F, et al. Bcl-2 functionally interacts with inositol 1,4,5-trisphosphate receptors to regulate calcium release from the ER in response to inositol 1,4,5-trisphosphate. J Cell Biol 2004;166:193-203.
25. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004;116:205-19.
26. Li C, Wang X, Vais H, Thompson CB, Foskett JK, White C. Apoptosis regulation by Bcl-x(L) modulation of mammalian inositol 1,4,5-trisphosphate receptor channel isoform gating. Proc Natl Acad Sci USA 2007;104:12565-70.
27. Piwnica-Worms D, Kronauge JF, Chiu ML. Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium(l) in cultured chick myocardial cells. Mitochondrial and plasma membrane potential dependence. Circulation 1990;82:1826-38.
28. Aloi L, Zannetti A, Caraco C, Del Vecchio S, Salvatore M. Bcl-2 overexpression prevents 99mTc-MIBI uptake in breast cancer cell lines. Eur J Nucl Med Mol Imaging 2004;31:521-7.
29. Del Vecchio S, Zannetti A, Aloj L, Caraco C, Ciarmiello A, Salvatore M. Inhibition of early 99mTc-MIBI uptake by Bcl-2 anti-apoptotic protein overexpression in untreated breast carcinoma. Eur J Nucl Med Mol Imaging 2003;30:879-87.
30. Zannetti A, Del Vecchio S, Carriero MV, et al. Coordinate up-regulation of Sp1 DNA-binding activity and urokinase receptor expression in breast carcinoma. Cancer Res 2000;60:1546-51.
31. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Functional imaging of mul-tidrug-resistant P-glycoprotein with an organotechne-tium complex. Cancer Res 1993;53:977-84.
32. Yang CH, Huang CJ, Yang CS, et al. Gefitinib reverses chemotherapy resistance in gefitinib-insensi-tive multidrug resistant cancer cells expressing ATP-binding cassette family protein. Cancer Res 2005;65:6943-9.
33. Elkind NB, Szentpetery Z, Apati A, et al. Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). Cancer Res 2005;65:1770-7.
34. Nakamura Y, Oka M, Soda H, et al. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Cancer Res 2005;65:1541-6.
35. 2+-induced apoptosis through calcineurin dephosphorylation of BAD. Science 1999;284:339-43.
36. Shibasaki F, Kondo E, Akagi T, McKeon F. Suppression of signalling through transcription factor NF-AT by interactions between calcineurin and Bcl-2. Nature 1997;386:728-31.
37. 2+: a control point for apoptosis. Science 2003;300:135-9.
38. 2+ analyzed with an improved genetically encoded fluorescent sensor. Proc Natl Acad Sci U S A 2004;101:17404-9.
39. Gong Y, Somwar R, Politi K, et al. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med 2007;4:e294.
40. White C, Li C, Yang J, et al. The endoplasmic reticulum gateway to apoptosis by Bcl-X(L) modulation of the lnsP3R. Nat Cell Biol 2005;7:1021-8.
41. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-81.